SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-142852
Filing Date
2022-05-06
Accepted
2022-05-06 06:02:55
Documents
16
Period of Report
2022-05-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d351893d8k.htm   iXBRL 8-K 32187
2 EX-4.1 d351893dex41.htm EX-4.1 60046
3 EX-5.1 d351893dex51.htm EX-5.1 15325
4 EX-10.1 d351893dex101.htm EX-10.1 150198
8 GRAPHIC g351893g0505091845601.jpg GRAPHIC 6457
  Complete submission text file 0001193125-22-142852.txt   461713

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA agle-20220505.xsd EX-101.SCH 2851
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE agle-20220505_lab.xml EX-101.LAB 18758
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE agle-20220505_pre.xml EX-101.PRE 11707
10 EXTRACTED XBRL INSTANCE DOCUMENT d351893d8k_htm.xml XML 3472
Mailing Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746
Business Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

IRS No.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37722 | Film No.: 22898696
SIC: 2834 Pharmaceutical Preparations